While the Outperform rating suggests that Raymond James still sees M.D.C. Holdings as a favorable investment, the reduction in the price target could imply a tempered expectation for the stock's growth or a reflection of market conditions. This news is likely to be taken as a mixed signal by investors, which could result in a neutral short-term impact on the stock price.